Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003087218> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2003087218 endingPage "e16" @default.
- W2003087218 startingPage "e15" @default.
- W2003087218 abstract "Therapy of chronic HCV infection is based on the use of the combination of pegylated interferon and ribavirin. Sustained virological response (SVR), a negative HCV RNA 24 weeks following discontinuation of therapy, is the most important surrogate parameter to achieve. Actually, SVR is obtained in about 50% of patients with genotypes 1/4 and in 80% of the patients with genotypes 2/3. Patients infected with genotypes 1 or 4 must be treated for 48 weeks. But, if the patient achieves a rapid virological response (RVR), defined as a negative HCV RNA at week 4, we can consider a shortening of treatment. In patients with a slow response to treatment (HCV RNA only negative between weeks 12 and 24) the length of therapy must be extended to 72 weeks. For patients infected with genotypes 2 or 3 treatment should be planned for 24 weeks. New drugs are needed for non-responders and for those who are not good candidates to treatment. Several new oral agents, more potent, less toxic and allowing for shorter duration of treatment are being developed. These new drugs are designed to inhibit several viral enzymes. Results of recent clinical trials using inhibitors of NS3/4A protease or inhibitors of NS5B polymerase in combination with peginterferon/ribavirin are promising. These studies demonstrated that adding telaprevir or boceprevir (the protease inhibitors in the most advanced phases of evaluation) to peginterferon/ribavirin improved the rates of SVR in treatment-naïve and treatment-experienced patients. From these and other trials it was possible to conclude that the use of these new agents in monotherapy, owing to its relative low genetic barrier, was associated with a rapid development of resistance to the drugs and that the use of ribavirin was always necessary. These new agents will be available for general clinical use in the next years but they must be used as a complement of current therapy. Abstracts for SupplementInternational Journal of Infectious DiseasesVol. 14Preview Full-Text PDF Open Archive" @default.
- W2003087218 created "2016-06-24" @default.
- W2003087218 creator A5062914904 @default.
- W2003087218 date "2010-03-01" @default.
- W2003087218 modified "2023-10-18" @default.
- W2003087218 title "Hepatitis C Treatment Today and the Future" @default.
- W2003087218 doi "https://doi.org/10.1016/j.ijid.2010.02.1516" @default.
- W2003087218 hasPublicationYear "2010" @default.
- W2003087218 type Work @default.
- W2003087218 sameAs 2003087218 @default.
- W2003087218 citedByCount "0" @default.
- W2003087218 crossrefType "journal-article" @default.
- W2003087218 hasAuthorship W2003087218A5062914904 @default.
- W2003087218 hasBestOaLocation W20030872181 @default.
- W2003087218 hasConcept C126322002 @default.
- W2003087218 hasConcept C159047783 @default.
- W2003087218 hasConcept C2522874641 @default.
- W2003087218 hasConcept C2776408679 @default.
- W2003087218 hasConcept C2776455275 @default.
- W2003087218 hasConcept C2776461080 @default.
- W2003087218 hasConcept C2776999253 @default.
- W2003087218 hasConcept C2777159539 @default.
- W2003087218 hasConcept C2778159067 @default.
- W2003087218 hasConcept C2778715236 @default.
- W2003087218 hasConcept C2780040827 @default.
- W2003087218 hasConcept C2781426373 @default.
- W2003087218 hasConcept C2781463415 @default.
- W2003087218 hasConcept C71924100 @default.
- W2003087218 hasConcept C90924648 @default.
- W2003087218 hasConcept C98274493 @default.
- W2003087218 hasConceptScore W2003087218C126322002 @default.
- W2003087218 hasConceptScore W2003087218C159047783 @default.
- W2003087218 hasConceptScore W2003087218C2522874641 @default.
- W2003087218 hasConceptScore W2003087218C2776408679 @default.
- W2003087218 hasConceptScore W2003087218C2776455275 @default.
- W2003087218 hasConceptScore W2003087218C2776461080 @default.
- W2003087218 hasConceptScore W2003087218C2776999253 @default.
- W2003087218 hasConceptScore W2003087218C2777159539 @default.
- W2003087218 hasConceptScore W2003087218C2778159067 @default.
- W2003087218 hasConceptScore W2003087218C2778715236 @default.
- W2003087218 hasConceptScore W2003087218C2780040827 @default.
- W2003087218 hasConceptScore W2003087218C2781426373 @default.
- W2003087218 hasConceptScore W2003087218C2781463415 @default.
- W2003087218 hasConceptScore W2003087218C71924100 @default.
- W2003087218 hasConceptScore W2003087218C90924648 @default.
- W2003087218 hasConceptScore W2003087218C98274493 @default.
- W2003087218 hasLocation W20030872181 @default.
- W2003087218 hasOpenAccess W2003087218 @default.
- W2003087218 hasPrimaryLocation W20030872181 @default.
- W2003087218 hasRelatedWork W119403464 @default.
- W2003087218 hasRelatedWork W1590300762 @default.
- W2003087218 hasRelatedWork W1970780167 @default.
- W2003087218 hasRelatedWork W1975576681 @default.
- W2003087218 hasRelatedWork W2007894395 @default.
- W2003087218 hasRelatedWork W202745368 @default.
- W2003087218 hasRelatedWork W2253270656 @default.
- W2003087218 hasRelatedWork W2548149772 @default.
- W2003087218 hasRelatedWork W2755121454 @default.
- W2003087218 hasRelatedWork W2977483558 @default.
- W2003087218 hasVolume "14" @default.
- W2003087218 isParatext "false" @default.
- W2003087218 isRetracted "false" @default.
- W2003087218 magId "2003087218" @default.
- W2003087218 workType "article" @default.